Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

CEFTAZIDIME 2 GM VIAL

ceftazidime
$9.5080per EA

Strength

2 g/1

Manufacturer

Sagent Pharmaceuticals

NDC

25021012850

Classification

Generic

Dosage Form

INJECTION, POWDER, FOR SOLUTION

Route

INTRAVENOUS

Last Updated

8/22/2013

Active Ingredients

CEFTAZIDIME

Approval Type

Generic (ANDA)

FDA Application

ANDA062640

On Market Since

5/15/2008

Pharmacological Classes

Cephalosporin Antibacterial
Cephalosporins

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

0.0%

All

N/A

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

CEPHALEXIN 250 MG/5 ML SUSP
Generic
00093417774•Teva Pharmaceuticals USA Inc.
$0.0513
per ML
CEPHALEXIN 250 MG/5 ML SUSP
Generic
62135048149•Chartwell RX LLC
$0.0513
per ML
CEPHALEXIN 250 MG/5 ML SUSP
Generic
67877054568•Ascend Laboratories, LLC
$0.0513
per ML
CEPHALEXIN 250 MG/5 ML SUSP
Generic
68180044102•Lupin Pharmaceuticals Inc.
$0.0513
per ML
CEPHALEXIN 125 MG/5 ML SUSP
Generic
00093417574•Teva Pharmaceuticals USA Inc.
$0.0535
per ML
CEPHALEXIN 125 MG/5 ML SUSP
Generic
62135048049•Chartwell RX LLC
$0.0535
per ML
CEPHALEXIN 125 MG/5 ML SUSP
Generic
67877054468•Ascend Laboratories, LLC
$0.0535
per ML
CEPHALEXIN 125 MG/5 ML SUSP
Generic
68180044002•Lupin Pharmaceuticals Inc.
$0.0535
per ML
CEPHALEXIN 125 MG/5 ML SUSP
Generic
00093417573•Teva Pharmaceuticals USA Inc.
$0.0678
per ML
CEPHALEXIN 125 MG/5 ML SUSP
Generic
62135048042•Chartwell RX LLC
$0.0678
per ML

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy